AGONISTISCHE CD40-ANTIKÖRPER

Patent europeic · EP3684813 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3684813
Numer da la dumonda
EP18778857
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
19-09-2018
Publitgà
29-07-2020
Concedì
08-10-2025
La protecziun finescha il pli tard
18-09-2038
Proxima taxa annuala scadenta
30-09-2027
Classas IPC
A61K 39/395 (2006.01)
Prioritad
EP 17191974 19.09.2017
Dumonda PCT
PCT/EP2018/075388 19.09.2018
Publicaziun PCT
WO2019/057792 28.03.2019
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-10-2026

    Next annual fee due on

    Next annual fee due on
    30.09.2026 → 30.09.2027

    Published in Swissreg on 01.10.2026

  2. 19-08-2026

    Midada

    Published in Swissreg on 19.08.2026

  3. 30-12-2025

    Represchentant inscrit

    Representative
    BOVARD AG, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 30.12.2025

  4. 08-10-2025

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 08.10.2025

Partidas

Possessur

MAB Discovery GmbH

Tassilostraße 2, 82398 Polling, DE

Represchentant

Bovard AG

BOVARD AG

Optingenstrasse 16, 3013 Bern

Inventur

FISCHER, Stephan

82362 Weilheim, DE

BECKMANN, Karsten

85591 Vaterstetten, DE

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.